BACKGROUND: Most glioblastomas recur near prior radiation treatment sites. Future clinical success will require achieving and optimizing an "abscopal effect," whereby unirradiated neoplastic cells outside treatment sites are recognized and attacked by the immune system. Radiation combined with anti-programmed cell death ligand 1 (PD-L1) demonstrated modest efficacy in phase II human glioblastoma clinical trials, but the mechanism and relevance of the abscopal effect during this response remain unknown. METHODS: We modified an immune-competent, genetically driven mouse glioma model (forced platelet derived growth factor [PDGF] expression + phosphatase and tensin homolog loss) where a portion of the tumor burden is irradiated (PDGF) and another unirradiated luciferase-expressing tumor (PDGF + luciferase) is used as a readout of the abscopal effect following systemic anti-PD-L1 immunotherapy. We assessed relevance of tumor neoepitope during the abscopal response by inducing expression of epidermal growth factor receptor variant III (EGFRvIII) (PDGF + EGFRvIII). Statistical tests were two-sided. RESULTS: Following radiation of one lesion, anti-PD-L1 immunotherapy enhanced the abscopal response to the unirradiated lesion. In PDGF-driven gliomas without tumor neoepitope (PDGF + luciferase, n = 8), the abscopal response occurred via anti-PD-L1 driven, extracellular signal-regulated kinase-mediated, bone marrow-derived macrophage phagocytosis of adjacent unirradiated tumor cells, with modest survival implications (median survival 41 days vs radiation alone 37.5 days, P = 0.03). In PDGF-driven gliomas with tumor neoepitope (PDGF + EGFRvIII, n = 8), anti-PD-L1 enhanced abscopal response was associated with macrophage and T-cell infiltration and increased survival benefit (median survival 36 days vs radiation alone 28 days, P = 0.001). CONCLUSION: Our results indicate that anti-PD-L1 immunotherapy enhances a radiation- induced abscopal response via canonical T-cell activation and direct macrophage activation in glioblastoma.
BACKGROUND: Most glioblastomas recur near prior radiation treatment sites. Future clinical success will require achieving and optimizing an "abscopal effect," whereby unirradiated neoplastic cells outside treatment sites are recognized and attacked by the immune system. Radiation combined with anti-programmed cell death ligand 1 (PD-L1) demonstrated modest efficacy in phase II humanglioblastoma clinical trials, but the mechanism and relevance of the abscopal effect during this response remain unknown. METHODS: We modified an immune-competent, genetically driven mouseglioma model (forced platelet derived growth factor [PDGF] expression + phosphatase and tensin homolog loss) where a portion of the tumor burden is irradiated (PDGF) and another unirradiated luciferase-expressing tumor (PDGF + luciferase) is used as a readout of the abscopal effect following systemic anti-PD-L1 immunotherapy. We assessed relevance of tumor neoepitope during the abscopal response by inducing expression of epidermal growth factor receptor variant III (EGFRvIII) (PDGF + EGFRvIII). Statistical tests were two-sided. RESULTS: Following radiation of one lesion, anti-PD-L1 immunotherapy enhanced the abscopal response to the unirradiated lesion. In PDGF-driven gliomas without tumor neoepitope (PDGF + luciferase, n = 8), the abscopal response occurred via anti-PD-L1 driven, extracellular signal-regulated kinase-mediated, bone marrow-derived macrophage phagocytosis of adjacent unirradiated tumor cells, with modest survival implications (median survival 41 days vs radiation alone 37.5 days, P = 0.03). In PDGF-driven gliomas with tumor neoepitope (PDGF + EGFRvIII, n = 8), anti-PD-L1 enhanced abscopal response was associated with macrophage and T-cell infiltration and increased survival benefit (median survival 36 days vs radiation alone 28 days, P = 0.001). CONCLUSION: Our results indicate that anti-PD-L1 immunotherapy enhances a radiation- induced abscopal response via canonical T-cell activation and direct macrophage activation in glioblastoma.
Authors: Makiko Mizutani; Paula A Pino; Noah Saederup; Israel F Charo; Richard M Ransohoff; Astrid E Cardona Journal: J Immunol Date: 2011-11-11 Impact factor: 5.422
Authors: Matija Snuderl; Ladan Fazlollahi; Long P Le; Mai Nitta; Boryana H Zhelyazkova; Christian J Davidson; Sara Akhavanfard; Daniel P Cahill; Kenneth D Aldape; Rebecca A Betensky; David N Louis; A John Iafrate Journal: Cancer Cell Date: 2011-12-01 Impact factor: 31.743
Authors: Orin Bloch; Courtney A Crane; Rajwant Kaur; Michael Safaee; Martin J Rutkowski; Andrew T Parsa Journal: Clin Cancer Res Date: 2013-04-23 Impact factor: 12.531
Authors: Genevieve P Hartley; Lyndah Chow; Dylan T Ammons; William H Wheat; Steven W Dow Journal: Cancer Immunol Res Date: 2018-07-16 Impact factor: 11.151
Authors: Sydney R Gordon; Roy L Maute; Ben W Dulken; Gregor Hutter; Benson M George; Melissa N McCracken; Rohit Gupta; Jonathan M Tsai; Rahul Sinha; Daniel Corey; Aaron M Ring; Andrew J Connolly; Irving L Weissman Journal: Nature Date: 2017-05-17 Impact factor: 49.962
Authors: Yizheng Yao; Jun Wang; Yi Liu; Yuan Qu; Kaikai Wang; Yang Zhang; Yuxin Chang; Zhi Yang; Jie Wan; Junfeng Liu; Hiroshi Nakashima; Sean E Lawler; E Antonio Chiocca; Choi-Fong Cho; Fengfeng Bei Journal: Nat Biomed Eng Date: 2022-10-10 Impact factor: 29.234
Authors: Pranjali P Kanvinde; Adarsha P Malla; Nina P Connolly; Frank Szulzewsky; Pavlos Anastasiadis; Heather M Ames; Anthony J Kim; Jeffrey A Winkles; Eric C Holland; Graeme F Woodworth Journal: Glia Date: 2021-02-27 Impact factor: 7.452
Authors: Erin F Simonds; Edbert D Lu; Oscar Badillo; Shokoufeh Karimi; Eric V Liu; Whitney Tamaki; Chiara Rancan; Kira M Downey; Jacob Stultz; Meenal Sinha; Lauren K McHenry; Nicole M Nasholm; Pavlina Chuntova; Anders Sundström; Vassilis Genoud; Shilpa A Shahani; Leo D Wang; Christine E Brown; Paul R Walker; Fredrik J Swartling; Lawrence Fong; Hideho Okada; William A Weiss; Mats Hellström Journal: J Immunother Cancer Date: 2021-06 Impact factor: 13.751
Authors: Maximilian Rauch; Daniel Tausch; Susanne Stera; Oliver Blanck; Robert Wolff; Markus Meissner; Hans Urban; Elke Hattingen Journal: J Neurooncol Date: 2021-03-24 Impact factor: 4.130
Authors: Brian M Andersen; Camilo Faust Akl; Michael A Wheeler; E Antonio Chiocca; David A Reardon; Francisco J Quintana Journal: Nat Rev Cancer Date: 2021-09-28 Impact factor: 69.800